Frits van Alphen gets Memo CDO job – The Pharma Letter
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO).
Former chief medical officer (CMO) at Vifor Pharma, Frits van Alphen, has taken the role, succeeding Gerald Parzmair, who has stepped down to pursue other opportunities.
Dr van Alphen has 30 years of international experience in clinical development and medical affairs in companies ranging from start-ups to big pharma, with expertise in nephrology and rare diseases, most recently with the development and sale of Inositec to Vifor Pharma.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Try before you buy
7 day trial access
Become a subscriber
Or £77 per month
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
The Pharma Letter
39-43 Putney High Street, Putney
London, SW15 1SP
United Kingdom
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze
source
This is a newsfeed from leading technology publications. No additional editorial review has been performed before posting.
